Two Cases of Treatment with Intrathecal Rituximab for Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin's lymphoma (NHL), usually composed of diffuse large B-cells.Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited.In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis.Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy.However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis.There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy.(